|
| Status |
Public on Mar 06, 2024 |
| Title |
Splicing targeting approaches highlight actionable vulnerabilities in advanced prostate cancer [22Rv1] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
To investigate if pharmacological inhibition of splicing could uncover novel actionable vulnerabilities in CRPC, we profiled the genome-wide transcriptional changes elicited in 22Rv1 cells by treatment with three drugs that inhibit the splicing through different molecular targets: i. Pladienolide B, that impairs the activity of SF3B1; ii. Indisulam that promote degradation of the splicing factor RBM39; iii. THZ531 inhibits the cyclin dependent kinases (CDK) 12 and 13.
|
| |
|
| Overall design |
Poly-A plus RNA-sequencing of 22Rv1 cells treated with Indisulam (3.3µM, 12hrs), or Pladienolide B (10nM, 6hrs) or THZ531 (200nM, 6hrs) or DMSO as control.
|
| |
|
| Contributor(s) |
Antonioni A, Caggiano C, Naro C, Jolly A, de la Grange P, Paronetto MP, Sette C |
| Citation(s) |
38413979 |
| |
| Submission date |
Jun 12, 2023 |
| Last update date |
Mar 06, 2024 |
| Contact name |
Pierre de la Grange |
| E-mail(s) |
pierre.delagrange@genosplice.com
|
| Organization name |
GenoSplice technology
|
| Department |
Paris Biotech Santé
|
| Street address |
29, rue du Faubourg Saint-Jacques
|
| City |
Paris |
| ZIP/Postal code |
75014 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA982834 |
Less...
More...